Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months

The highly selective BCL2 inhibitor venetoclax achieves deep responses in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL), including undetectable minimal residual disease (uMRD). We retrospectively reviewed 62 patients with CLL treated with venetoclax to investigate the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Lew, Thomas E., Anderson, Mary Ann, Lin, Victor S., Handunnetti, Sasanka M., Came, Neil A., Blombery, Piers, Westerman, David A., Wall, Meaghan, Tam, Constantine S., Roberts, Andrew W., Seymour, John F.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6960473/
https://ncbi.nlm.nih.gov/pubmed/31935286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000864
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados